These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 1568524)

  • 1. Influence of prostaglandin E1 on slight proteinuria in non-azotaemic diabetics.
    Okada S; Sato K; Higuchi T; Ichiki K; Tanokuchi S; Ishii K; Hamada H; Ota Z
    J Int Med Res; 1992 Feb; 20(1):94-7. PubMed ID: 1568524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of prostaglandin E1 on heavy proteinuria in slightly azotaemic diabetics.
    Okada S; Sato K; Higuchi T; Ichiki K; Tanokuchi S; Ishii K; Hamada H; Ota Z
    J Int Med Res; 1991; 19(2):171-3. PubMed ID: 1864454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased creatinine clearance which may be observed during prostaglandin E1 therapy: is it reversible with discontinuation of therapy?
    Okada S; Miyai Y; Sato K; Higuchi T; Ichiki K; Tanokuchi S; Ishii K; Hamada H; Ota Z
    J Int Med Res; 1991; 19(6):493-6. PubMed ID: 1773910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of prostaglandin E1 on the renin-aldosterone system in patients with diabetic nephropathy.
    Okada S; Ichiki K; Tanokuchi S; Ishii K; Hamada H; Ota Z
    J Int Med Res; 1993; 21(3):126-32. PubMed ID: 8299855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does a dose of 40 micrograms/day prostaglandin E1 reduce creatinine clearance in a patient with diabetic nephropathy of the nephrotic type?
    Okada S; Hamada H; Ichiki K; Tanokuchi S; Ishii K; Ota Z; Hiraki Y
    J Int Med Res; 1992 Apr; 20(2):190-6. PubMed ID: 1521675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
    Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
    J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of prostaglandin E1 on renal haemodynamics in a patient with diabetic nephropathy.
    Okada S; Ogino Y; Ichiki K; Tanokuchi S; Ishii K; Hamada H; Ota Z; Hiraki Y
    J Int Med Res; 1991; 19(6):497-500. PubMed ID: 1773911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of captopril on heavy proteinuria in azotemic diabetics.
    Taguma Y; Kitamoto Y; Futaki G; Ueda H; Monma H; Ishizaki M; Takahashi H; Sekino H; Sasaki Y
    N Engl J Med; 1985 Dec; 313(26):1617-20. PubMed ID: 3906398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of aspirin-dipyridamole reduces proteinuria in diabetic nephropathy.
    Hopper AH; Tindall H; Davies JA
    Nephrol Dial Transplant; 1989; 4(2):140-3. PubMed ID: 2496357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin receptor blocker and N-acetyl cysteine for reduction of proteinuria in patients with type 2 diabetes mellitus.
    Rasi Hashemi S; Noshad H; Tabrizi A; Mobasseri M; Tayebi Khosroshahi H; Heydarnejad M; Khalaj MR; Aghamohammadzadeh N
    Iran J Kidney Dis; 2012 Jan; 6(1):39-43. PubMed ID: 22218118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic effect of prostaglandin E1 on diabetic nephropathy: a one-year follow-up study].
    Li PF; Mu YR; Xin Y; Qu Y; Liao L
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):482-5. PubMed ID: 20335115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of blood pressure-reducing therapy with captopril on tubular marker excretion in type-1 diabetics with nephropathy].
    Ratzmann KP; Raskovic M; Schimke E
    Dtsch Med Wochenschr; 1994 Jun; 119(22):796-800. PubMed ID: 8205941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy.
    Kim MJ; Song JH; Suh JH; Lee SW; Kim GA
    Yonsei Med J; 2003 Jun; 44(3):463-72. PubMed ID: 12833584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of low-protein, very-low-phosphorus diet on diabetic renal insufficiency with proteinuria.
    Shichiri M; Nishio Y; Ogura M; Marumo F
    Am J Kidney Dis; 1991 Jul; 18(1):26-32. PubMed ID: 2063852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.
    Shimoike T; Inoguchi T; Umeda F; Nawata H; Kawano K; Ochi H
    Metabolism; 2000 Aug; 49(8):1030-5. PubMed ID: 10954022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of the clinical effect of ligustrazine on diabetic nephropathy.
    Wang B; Ni Q; Wang X; Lin L
    Am J Chin Med; 2012; 40(1):25-37. PubMed ID: 22298446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of selective inhibition of thromboxane synthesis on renal function in diabetic nephropathy.
    Kontessis PS; Jones SL; Barrow SE; Stratton PD; Alessandrini P; De Cosmo S; Ritter JM; Viberti GC
    J Lab Clin Med; 1993 Mar; 121(3):415-23. PubMed ID: 8445289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of urinary TGF-β1 in patients with diabetes mellitus and normal controls.
    Tsapenko MV; Nwoko RE; Borland TM; Voskoboev NV; Pflueger A; Rule AD; Lieske JC
    Clin Biochem; 2013 Oct; 46(15):1430-5. PubMed ID: 23685222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy.
    Kadian S; Mahadevan N; Balakumar P
    Eur J Pharmacol; 2013 Jan; 698(1-3):388-96. PubMed ID: 23085026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind trial of perindopril and nitrendipine in incipient diabetic nephropathy.
    Kopf D; Schmitz H; Beyer J; Frank M; Bockisch A; Lehnert H
    Diabetes Nutr Metab; 2001 Oct; 14(5):245-52. PubMed ID: 11806464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.